ROCKVILLE, MD — May 13, 2015 — Therabron Therapeutics, Inc. (Therabron), a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, today announced that the European Medicines Agency (EMA) has granted the Company’s lead product candidate, CG100, an orphan drug designation for the prevention of bronchopulmonary dysplasia (BPD). An orphan drug designation allows products receiving a marketing authorization from the EMA to have up to ten years of market exclusivity in the European Union (EU). Therabron previously secured an orphan designation for the prevention of BPD from the US Food and Drug Administration (FDA). For more information, click here.